tundup, thank you very much for this clear and layman friendly explanation. Between your posts and BDAZ I'm beginning to get a feel for why it takes so much time and I am beginning to understand that it very important to get it right in terms of clinical trial design.

Thanks also for your hypothesis re the FDA. Scientific and medical communities tend to be, justifiably, very conservative. Entrenched beliefs are very difficult to change even as evidence mounts against them (e.g. I think it was called the "7 Country Study" which set the food guide standards for 40 years and now that study has been refuted).

Don has often stated that RVX/Zenith are 6 to 8 years ahead of anyone re their epigenetic experimentation and scientific knowledge (patents,etc). I've really wondered about that but the knowledge with the current post hoc analysis seems to support that claim particularly related to the complex epigenetic effects of rvx-208 and it's dramatic reduction of MACE events. When somebody like Crick of Watson of the Double Helix says to pay attention to epigenetics it's assuring that RVX listened 8 years ago.

Epigenetics is in it's infancy and BP tends to lag innovation so no wonder they are slow to get the message.

I don't think RVX would have been able to attract the scientific talent pool they have without these scientists feeling that there is a potential blockbuster and also that they have the opportunity to be involved in many potential breakthroughs with the Zenith portfolio.

Once the scientific momentum builds the uptake for epigenetics will be rapid. Don, Ken and others are spreading the word and this should give further substance to RVX.

Thanks again.

GLTA

Toinv